Gour Medical lists on the Marché Libre Euronext Paris

05.12.2016 09:19

Related tags

Gour Medical announces the successful completion of its direct listing on Marché Libre Euronext Paris. The pharmaceutical company is dedicated to the development and marketing of veterinary drugs for mature pets.

Having first identified and acquired a number of drug candidates from the human health industry, Gour Medical has then been able to maximize their clinical and market potential in order to treat mature pets. Gour Medical has signed exclusive and worldwide licensing agreements with several bio-pharmaceutical leaders in human health for the development and marketing of their products for veterinary use. The bio-pharmaceutical leaders include Actelion in Switzerland, Medicom Healthcare in the United Kingdom, Solmic Research in Germany and the US-based world leader in animal health diagnostics— Idexx Laboratories, Inc..

Gour Medical’s portfolio includes four innovative products / product lines, some of which will be ready to be marketed shortly:

  • A line of ophthalmological products, with planned market launch during the second half of 2017;
  • Gour-153, a painkiller scheduled to be marketed in 2018;
  • Gour-713 and Gour-419, two products currently under development for the treatment of anxiety and atopic dermatitis respectively.

A growing market
The pet health market, which is currently estimated at € 9.4 billion worldwide, is experiencing strong and consistent growth and is expected to reach more than € 13 billion by 2020 (CAGR +7%). This trend looks sustainable, as pets are increasingly well fed and cared for. Indeed, the life expectancy of dogs’ and cats’ continues to increase and aging animals are the most likely to contract diseases.

Gour Medical intends to extend its comprehensive portfolio to prepare for the market launch of its first products and strengthen its team. Gour Medical also intends to take advantage of the dynamism, strong demand and steep growth of its core target: mature pets’ health. Drawing on its successful listing on the Marché Libre Euronext Paris, Gour Medical hopes to attract new investors to support its ambitious development strategy and in due course to transfer its listed shares to Alternext Paris.

Gour Medical’s listing on the Marché Libre
Gour Medical shares are being listed on the Marché Libre Euronext Paris stock exchange through direct listing (ISIN code: CH0342399851; Ticker: MLGML). The issued share capital of Gour Medical currently comprises 2,830,000 shares. Based on a price per share of €5.69 at the time of listing, the Company’s market capitalization is €16.1 million.

Euronext Marché Libre Paris
The Euronext Marché Libre Paris was established in 1996 to target French and foreign SMEs that wish to join a stock exchange, but who cannot meet the criteria for admission on Euronext’s regulated markets. Consequently, issuers of the financial instruments that are traded on the Marché Libre are not bound by requirements that apply to companies listed on a regulated market:

  • The accounting requirements are those determined by the company's legal form.
  • There is no minimum public holding requirement regarding the issuer's securities.
  • Euronext Paris does not receive specific information concerning events that might affect the company's net worth or legal situation, and consequently, they cannot necessarily inform market users of such events.

However, issuers who market their securities to the public (with the meaning of ‘appel public à l’épargne’) are subject to relevant ongoing disclosure provisions of the the Autorité des marches financiers general regulations.

Please login or
register to comment

Please login or sign up to comment. Commenting guidelines

Please login or
register to use the
bookmark feature

Related News

Related tags

Read more about

Principal

First Musketeer Award

Individuals and organisations that are contributing to the development of the Swiss startup ecosystem will be awarded with the Musketeer Award at the Swiss Startup day. Public Voting is now open.

Partners

Contributors